期刊文献+

黏蛋白MUC1、MUC2在十二指肠腺瘤的表达及意义

Expression and signifiance of MUC1 and MUC2 in duodenal adenoma
下载PDF
导出
摘要 目的研究黏蛋白MUC1、MUC2在十二指肠腺瘤中的表达及意义。方法应用免疫组化方法检测了40例十二指肠腺瘤(其中9例癌变)和10例正常十二指肠黏膜MUC1和MUC2的表达。结果40例十二指肠腺瘤中,低级别异型增生9例,高级别异型增生22例,癌变9例;在十二指肠腺瘤伴低级别异型增生、高级别异型增生、腺瘤癌变中,MUC1阳性表达率分别为44.4%(4/9)、81.8%(18/22)、100%(9/9),阳性评分分别为1.33、5.86、8.67,MUC1呈逐步上调趋势(P<0.05);另一方面,MUC2的阳性表达率分别为100%(9/9)、72.7%(16/22)、11.1%(1/9),阳性评分分别为6.33、5.86、8.67,MUC2呈逐步下调趋势(P<0.05)。结论 MUC1、MUC2可能是评估十二指肠腺瘤恶性潜能的有用的标记物。 Objective To evaluate the expression and significance of MUC1 and MUC2 in duodenal adenoma. Methods The expressions of MUC1 and MUC2 were examined by immunohistochemical staining in 40 duodenal adenoma (including 9 adenoma with carcinomas)and 10 normal duodenal mucosa specimens. Results In 40 duodenal adenoma, there were 9 cases with low-grade dysplasia ( LGD ), 22 cases with high-grade dysplasis (HGD) and 9 cases with adenocarcinomas(AC). The positive expression rate of MUC1 were 44.4% (4/9),81.8% (18/22), 100% (9/9)in duodenal adenoma with LGD, HGD and AC respectively, and the score of MUC1 were 1.33,5.86,8.67 respectively, and the expression of MUC1 was up-regulation in LGD-HGD-AC ( P 〈 0.05 ) ; On the other hand, the positive expression rate of MUC2 were 100% (9/9) ,72.7% (16/22), 11.1% (1/9)in duodenal adenoma with LGD, HGD and AC respectively,the score of MUC2 were 6.33 ~5.86,8.67 respectively, and the expression of MUC2 was down-regulation in LGD-HGD-AC. (P 〈 0. 05 ). Conclusion MUC1 and MUC2 may be useful makers for evaluating malignant potential of duodenal adenoma.
出处 《哈尔滨医科大学学报》 CAS 北大核心 2012年第3期257-260,共4页 Journal of Harbin Medical University
基金 国家自然科学基金资助项目(30472035)
关键词 十二指肠腺瘤 MUC1 MUC2 duodenal adenoma MUC1 MUC2
  • 相关文献

参考文献20

  • 1Albore-Saavedra J, Schwartz AM, Batich K, et al. Cancers of the ampulla of vater: Demographics, morphology, and survival based on 5625 cases from the SEER progam [ J ]. Surg Oncol, 2009, 100 (7) : 598-605.
  • 2Das A, Neugnt AL, Cooper GS, et al, Association of ampullary and colorectal malignancies[ J ]. Cancer,2004,100 (3) : 524-530.
  • 3Sobol S, Cooperman AM. Villous adenoma of the ampulla of Vater [ J ]. Gastro-entemlogy, 1978,75 ( 1 ) : 107-109.
  • 4Takashima M, Ueki T, Nagai E, et al. Carcinoma of the ampulla of Vater associated with or without adenoma: a clinicopathologic a- nalysis of 198 cases with reference to p53 and Ki-67 immunohisto- chemical expressions [ J ]. Mod Pathol, 2000, 13 ( 12 ) : 1300-1307.
  • 5Rachagani S, Tones MP, Moniaux N, et al: Current status of mucins in the diagnosis and therapy of cancer [ J ]. Biofactors, 2009,35(6) : 509-527.
  • 6Aksoy N, Akinci OF. Mucin macromolecules in normal, adeno- matous, and carcinomatous colon : evidence for the neotransforma- tion [ J ]. Macromol Biosci, 2004,4 ( 5 ) : 483-496.
  • 7Kozuka S,Tsubone M, Yamaguchi A,et al. Adenomatous residue in cancerous papilla of rater[ J]. Gut, 1981,22(12) :1031-1034.
  • 8Ryan DP, Schapiro RH, Warshaw AL. Villous tumors of the duode- num [ J ]. Ann-Surg, 1986,203 ( 3 ) : 301-306.
  • 9Buisine MP, Descreumaux P, Debailleul V, et al . Abnormalities in mucin gene. Expression in Crohn "s n [ J ]. Inflation Bowel Dis, 1999,5 ( 1 ) :24-32.
  • 10张立新,李春海.MUC1粘蛋白的免疫生物学作用及其在肿瘤生物学治疗中的应用[J].中国肿瘤生物治疗杂志,2000,7(3):165-170. 被引量:33

二级参考文献12

  • 1刘学仁,邵永孚.MUC1粘蛋白基因表达在大肠癌淋巴结微小转移诊断中的应用[J].中华肿瘤杂志,1996,18(6):483-483. 被引量:3
  • 2Xing P X,Immunol Cell Biol,1989年,67卷,2期,183页
  • 3Apostolopoulos V,Mckenzie LFC, Pietersz GA. Breast cancer immunotherapy: Current status and future prospects. Immunol Cell Biology,1996,74:457
  • 4Apostolopoulos V,Mckenzie LFC. Cellular mucins: targets for immunotherapy. Crit Rev Immunol,1994,14(3-4):293
  • 5Lightenberg, Buijs F, Vos HL et al. Suppression of cellular aggregation by high level of episiallin. Cancer Reserch,1992,52:2318
  • 6Von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol, 2000,18(3): 574
  • 7Adluri S, Gilewski T, Zhang S et al. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. British J Cancer, 1999,79(11/12):1806
  • 8Acres B, Apostolopoulos V, Balloul JM et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother,2000,48:588
  • 9张立新,李春海,陆雅芬,孙丽亚.血清MUC1粘蛋白IRMA及其初步临床应用[J].中华核医学杂志,1997,17(4):211-213. 被引量:12
  • 10阎洪彦,王立顺.MUC1粘蛋白—肿瘤生物治疗的新靶点[J].国外医学(免疫学分册),2000,23(2):113-115. 被引量:9

共引文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部